Saturday 17 October 2026
Export GANX’s income statement to Excel — free account
Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
1.26
0.07
−5.26%
Follow GANX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Piotroski F-Score |
— | — | — | — | 5 | 3 | 1 | — | — |
P/S ratio |
— | 1,039.00 | 1,039.00 | 1,039.00 | 334.52 | 210.04 | 241.83 | — | — |
Altman Z-Score |
— | — | — | — | 7.61 | 1.48 | (1.79) | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (32.50) | 3.00 | 11.72 | 0.63 | (8.07) | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Beneish M-Score |
— | — | — | (3.00) | 4.46 | (2.45) | — | — | — |
P/Operating CF |
— | (22.96) | (22.96) | (22.96) | (13.31) | (9.86) | (8.34) | — | — |
P/B ratio |
— | 4.84 | 4.84 | 4.84 | 1.59 | 2.04 | 3.75 | — | — |
Price to Tangible BV |
— | 4.84 | 4.84 | 4.84 | 1.59 | 2.04 | 3.75 | — | — |
EV/Sales |
— | 804.89 | 804.89 | 804.89 | 115.21 | 103.47 | 158.75 | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | (7.18) | (7.18) | (7.18) | (1.54) | (1.29) | (1.64) | — | — |
EV/FCF |
— | (7.13) | (7.13) | (7.13) | (1.53) | (1.28) | (1.64) | — | — |
Quick Ratio |
— | — | 0.35 | 3.55 | 14.45 | 4.88 | 3.39 | 2.66 | 6.22 |
Current Ratio |
— | — | 0.49 | 4.25 | 14.78 | 5.11 | 3.59 | 2.97 | 6.63 |
Net Debt/EBITDA |
— | 0.00 | 0.05 | 1.95 | 2.62 | 1.10 | 0.73 | 0.49 | 1.10 |
Debt/Assets |
0.00% | 0.00% | 30.43% | 7.69% | 1.78% | 2.50% | 3.05% | 3.62% | 1.76% |
Debt/Equity |
— | 0.00 | (0.45) | 0.12 | 0.02 | 0.03 | 0.05 | 0.06 | 0.02 |
Asset Turnover |
— | 0.00 | 0.13 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.67 | 0.85 | 0.91 | 0.89 | 0.84 | 0.85 | 0.92 | 0.92 |
Capex/Depreciation |
— | (11.43) | (5.27) | (2.17) | (6.08) | (1.85) | (0.18) | (0.27) | 0.00 |
| — | 0.00% | (76.27%) | (124.41%) | (67.73%) | (65.52%) | (141.57%) | (204.95%) | (155.66%) | |
| — | 0.00% | (664.36%) | (69.71%) | (57.18%) | (55.77%) | (104.28%) | (132.83%) | (115.39%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 0.00% | 508.67% | (51.83%) | (39.38%) | (102.81%) | (171.88%) | (261.86%) | (106.34%) |
Average Days of Receivables |
— | 0.00 | 74.24 | 107.35 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
— | 4,014.08% | 3,840.68% | 7,817.30% | 4,341.94% | 5,979.51% | 20,870.65% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 1,077.67% | 1,344.31% | 4,322.15% | 4,137.52% | 6,809.35% | 19,542.93% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 282.35% | 508.73% | 1,089.51% | 5,903.99% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.19 | 0.19 | 0.19 | 0.61 | 0.41 | 0.25 | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | (11.88%) | (11.88%) | (11.88%) | (26.52%) | (45.68%) | (47.11%) | — | — |
Free Cash Flow Yield |
— | (10.86%) | (10.86%) | (10.86%) | (22.57%) | (38.47%) | (39.98%) | — | — |
Revenue per Share |
— | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.33) | (0.83) | (1.21) | (1.22) | (1.24) | (1.45) | (0.82) | (0.56) |
Capex per Share |
— | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.33) | (0.84) | (1.22) | (1.23) | (1.25) | (1.45) | (0.83) | (0.56) |
Cash per Share |
— | 0.00 | 0.13 | 2.80 | 3.63 | 1.69 | 1.29 | 0.45 | 0.63 |
Shareholders Equity per Share |
— | 0.00 | (0.20) | 2.31 | 3.43 | 1.59 | 0.97 | 0.32 | 0.56 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (0.20) | 2.31 | 3.43 | 1.59 | 0.97 | 0.32 | 0.56 |
Free Cash Flow |
— | (0.75) | (1.88) | (3.26) | (12.46) | (14.81) | (18.88) | (18.90) | (18.47) |
Working Capital |
— | — | (0.45) | 6.87 | 35.17 | 16.97 | 12.83 | 7.69 | 18.88 |
Capital Expenditures |
— | (0.01) | (0.01) | (0.02) | (0.09) | (0.12) | (0.02) | (0.02) | — |
Net Current Asset Value |
— | 0.00 | (0.68) | 5.59 | 33.55 | 15.87 | 11.75 | 6.82 | 17.98 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
— | 0.39 | 0.33 | 0.72 | 0.57 | 0.85 | 0.28 | 0.00 | — |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.14 | 0.32 | 0.15 | 0.44 | 0.66 | 0.81 | 1.26 |
Cash ROIC |
— | 0.00% | (3,466.30%) | (22.58%) | (17.21%) | (37.38%) | (63.06%) | (104.03%) | (46.39%) |
Accounts Receivable Turnover |
— | 0.00 | 0.74 | 3.42 | 1.62 | 0.72 | 0.00 | — | — |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
— | — | 0.06 | 0.01 | 0.10 | 0.19 | — | — | — |
Average Payables |
— | — | 0.56 | 0.56 | 0.76 | 1.09 | 1.47 | 1.13 | 0.89 |
Average Assets |
— | 0.00 | 0.33 | 5.13 | 24.29 | 31.54 | 21.35 | 15.37 | 17.47 |
Average Common Equity |
— | — | 2.88 | 2.88 | 20.51 | 26.85 | 15.73 | 9.96 | 12.95 |
Columns are period end dates